Modified immune cells for T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of T-cell lymphoma that has a marker called CD7 on the cancer cells.
- Your lymphoma has come back or not gotten better after standard chemotherapy, and you have few other treatment options left.
- You are between 14 and 70 years old.
- You are generally able to take care of yourself (ECOG score 0-2).
- You do not have serious heart, lung, kidney, or bleeding problems, active infections, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Hear when a new T-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.